Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Dan Gold’s Hedge Fund Adds Oncothyreon

Dan Gold’s hedge fund: Oncothyreon Inc (USA) (NASDAQ:ONTY) was just added to the equity portfolio of Daniel Gold’s hedge fund QVT Financial. In a filing with the Securities and Exchange Commission, QVT disclosed that it owns almost 3.7 million shares of Oncothyreon, the value of the stake amounting to $6.7 million. Through the acquisition, QVT holds about 5.8% of the company.

Oncothyreon Inc (USA) (NASDAQ:ONTY)

Oncothyreon is a company engaged in production of therapeutic products for the cancer  treatment. The company expanded its net loss to $18 million for the second quarter, from last year’s amount of $8.1 million. At the same time, the company recently appointed the former  Executive Vice President and Head of Research and Development and Technical Operations at Onyx Pharmaceuticals, Dr. Ted W. Love, to its Board of Directors.

Aside from QVT Financial, it is important to mention some other hedge funds who are bullish on Oncothyreon, according to our database. As follows, in the latest round of 13F filings, Israel Englander’s Millennium Management is the hedge fund with the second-largest stake, which involves 2.1 million shares. It is followed by First Eagle Investment Management, which disclosed ownership of 1.3 million shares, and Adage Capital Management, managed by Phill Gross and Robert Atchinson, which owned 950,000 shares at the end of the last quarter. Check back here for more updates on Dan Gold’s hedge fund.

Recommended Reading:

There’s More to Carl Icahn’s Portfolio Than Just Apple and Dell

Warren Buffett Portfolio: How He’s Playing The Small-Caps

Value Investing Congress 2013: Small-Cap ‘Needles in a Haystack’ From Guy Gottfried

Disclosure: none

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.